Transdermal estradiol equals LHRH agonists in androgen deprivation therapy (ADT) in locally advanced prostate cancer. Both methods of treatment equally reduce the risk of distant metastases. The estradiol patch causes fewer vasomotor symptoms such as hot flashes. The study showed that estradiol is comparably effective to standard treatment with LHRH agonists. These agonists are among the common drugs to achieve androgen deprivation in advanced prostate cancer. Estradiol thus represents an alternative with a lower incidence of side effects.